NCT06170593 (ATM-2201) is a NA clinical trial of Triamcinolone Injection in Acne Vulgaris, sponsored by ACOM Labs.

Who is sponsoring NCT06170593?

NCT06170593 is sponsored by ACOM Labs.

What drugs are being tested in NCT06170593?

Interventions in NCT06170593: Triamcinolone Injection.

What condition does NCT06170593 study?

NCT06170593 studies Acne Vulgaris.

Is NCT06170593 still recruiting?

NCT06170593 is currently completed. Last updated 14 December 2023.

Last reviewed 2023-12-14 · How we verify

NCT06170593: ATM-2201

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intralesional Injections of Triamcinolone for Acne Vulgaris

Completed NA Last updated 14 December 2023

What this trial tests

NA trial testing Triamcinolone Injection in Acne Vulgaris in 20 participants. Completed in 14 February 2023.

Timeline

15 November 2022

Primary endpoint
31 January 2023

14 February 2023

Quick facts

Lead sponsor	ACOM Labs
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	15 November 2022
Primary completion	31 January 2023
Estimated completion	14 February 2023
Sites	1 location across United States

Drugs / interventions tested

Triamcinolone Injection — full drug profile →

Conditions studied

Acne Vulgaris — all drugs for Acne Vulgaris →

Sponsor

ACOM Labs

Who can join

18 and older, any sex, with Acne Vulgaris. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This proof-of-concept study seeks to investigate the safety of intralesional injections of triamcinolone for acne vulgaris lesions using an Intradermal Needle Adapter.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Intralesional triamcinolone for inflammatory acne: a comparative study of dose efficacy and investigation of a novel injection assistance device to enable self-administration of intralesional therapy.
Olson LB, Roberts CM, Dhawan SS, Reed AM, et al · · 2025 · PMID 40436743 · DOI 10.1080/09546634.2025.2504656

Verify or expand the search:

Other trials of Triamcinolone Injection

Trials testing the same drug.

NCT05364099 — Suprascapular Nerve Block for Treatment of Shoulder Pain in Individuals With Spinal Cord Injuries · Phase 4 · withdrawn
NCT04710719 — Post-Surgical Injection With Triamcinolone Versus Triamcinolone/Fluorouracil in Treatment of Keloids · NA · completed
NCT01873573 — Randomized Controlled Trial of Endoscopic Dilation: Triamcinolone Injection · NA · completed
NCT04058522 — Treatment of Subacromial Shoulder Pain by Individual or Group Physiotherapy Following Corticosteroid Injection · NA · completed

Other recruiting trials for Acne Vulgaris

Currently open trials in the same condition.

NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
NCT07474883 — Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris · EARLY_PHASE1 · recruiting
NCT07186413 — A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne · Phase 3 · recruiting
NCT07056673 — Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris Study · NA · recruiting
NCT07102186 — Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris · Phase 4 · recruiting

Other ACOM Labs trials

Trials by the same sponsor.

NCT06186596 — Self-Administered Intralesional Injections for Acne · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06170593 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ACOM Labs
Last refreshed: 14 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06170593.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing